Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation-Reference-Cited by-同舟云学术

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation

Published:2006-10-19 Issue:12 Volume:20 Page:2204-2207
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Karlsson C,Norin S,Kimby E,Sander B,Porwit MacDonald A,Nilsson B,Johansson E,Mellstedt H,Lundin J,Österborg A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404435.pdf

Reference8 articles.

1. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A . Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001; 2: 300–306.

2. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.

3. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

4. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484–490.

5. Tsimberidou A-M, Keating MJ . Richter's syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216–228.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia;Cancer Treatment Reviews;2023-11

2. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study;Leukemia Research;2022-11

3. Adverse Cutaneous Reactions to Chemotherapeutic Agents;Hospital-Based Dermatopathology;2020

Immunochemotherapy for Richter syndrome: current insights

;ImmunoTargets and Therapy;2019-02

5. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies;Annals of Hematology;2017-10-23